Tanmoy Mondal to Immunotherapy
This is a "connection" page, showing publications Tanmoy Mondal has written about Immunotherapy.
Connection Strength
0.403
-
Wamba BEN, Mondal T, Freenor V F, Shaheed M, Pang O, Bedinger D, Legembre P, Devel L, Bhatnagar S, Leiserowitz GS, Tushir-Singh J. Evolutionary regulation of human Fas ligand (CD95L) by plasmin in solid cancer immunotherapy. Nat Commun. 2025 Jul 01; 16(1):5748.
Score: 0.210
-
Mondal T, Shivange GN, Tihagam RG, Lyerly E, Battista M, Talwar D, Mosavian R, Urbanek K, Rashid NS, Harrell JC, Bos PD, Stelow EB, Stack MS, Bhatnagar S, Tushir-Singh J. Unexpected PD-L1 immune evasion mechanism in TNBC, ovarian, and other solid tumors by DR5 agonist antibodies. EMBO Mol Med. 2021 03 05; 13(3):e12716.
Score: 0.155
-
Shivange G, Mondal T, Lyerly E, Gatesman J, Tushir-Singh J. Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody. J Vis Exp. 2020 05 16; (159).
Score: 0.037